Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 06, 2023

Impact of TP53 on Outcomes of Patients With Myelofibrosis Undergoing HSCT

Blood

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
Blood 2023 Mar 20;[EPub Ahead of Print], N Gagelmann, A Badbaran, RB Salit, T Schroeder, C Gurnari, S Pagliuca, V Panagiota, C Rautenberg, B Cassinat, FR Thol, C Wolschke, M Robin, M Heuser, MT Rubio, JP Maciejewski, HC Reinhardt, BL Scott, N Kröger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading